122 related articles for article (PubMed ID: 8529065)
1. 3,4-dihydroxyphenylalanine (DOPA) decarboxylase deficiency and resultant high levels of plasma DOPA and dopamine in unfavorable neuroblastoma.
Ikeda H; Matsuyama S; Suzuki N; Takahashi A; Kuroiwa M
Hypertens Res; 1995 Jun; 18 Suppl 1():S209-10. PubMed ID: 8529065
[TBL] [Abstract][Full Text] [Related]
2. 3,4-dihydroxyphenylalanine (DOPA) metabolism in screening-detected and non-screening-detected neuroblastoma.
Ikeda H; Suzuki N; Takahashi A; Kuroiwa M; Matsuyama S
Pediatr Hematol Oncol; 1996; 13(1):21-32. PubMed ID: 8718500
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma.
Eldrup E; Clausen N; Scherling B; Schmiegelow K
Scand J Clin Lab Invest; 2001; 61(6):479-90. PubMed ID: 11681538
[TBL] [Abstract][Full Text] [Related]
4. Combined measurements of plasma aromatic L-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma.
Boomsma F; Ausema L; Hakvoort-Cammel FG; Oosterom R; Man in't Veld AJ; Krenning EP; Hahlen K; Schalekamp MA
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1045-52. PubMed ID: 2503383
[TBL] [Abstract][Full Text] [Related]
5. 3,4-dihydroxyphenylalanine (dopa) metabolism and retinoic acid induced differentiation in human neuroblastoma.
Ikeda H; Pastuszko A; Ikegaki N; Kennett RH; Wilson DF
Neurochem Res; 1994 Dec; 19(12):1487-94. PubMed ID: 7877718
[TBL] [Abstract][Full Text] [Related]
6. Plasma dopa and catecholamines in the diagnosis and follow-up of children with neuroblastoma.
Alvarado CS; Faraj BA; Kim TH; Camp VM; Bain RP; Ragab AH
Am J Pediatr Hematol Oncol; 1985; 7(3):221-7. PubMed ID: 3934994
[TBL] [Abstract][Full Text] [Related]
7. Determination of urinary vanillactic acid and plasma dihydroxyphenylalanine as markers of non-secreting neuroblastoma by high-performance liquid chromatography with electrochemical detection.
Jouve J; Bakri D; Herault J; Muh JP
J Chromatogr; 1991 Jul; 567(2):331-41. PubMed ID: 1939466
[TBL] [Abstract][Full Text] [Related]
8. Defective 3,4-dihydroxyphenylalanine decarboxylation to dopamine in hydralazine-treated hypertensive patients may be pyridoxine remediable.
Shigetomi S; Kuchel O
Am J Hypertens; 1993 Jan; 6(1):33-40. PubMed ID: 8427659
[TBL] [Abstract][Full Text] [Related]
9. Simple gas chromatographic analysis of plasma dopa and dopamine.
Mizuno Y
Clin Chim Acta; 1977 Jan; 74(1):11-9. PubMed ID: 832410
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of catecholamine biosynthesis by carbidopa and metyrosine in neuroblastoma.
Anton AH; Crumrine RS; Stern RC; Izant RJ
Pediatr Pharmacol (New York); 1983; 3(2):107-17. PubMed ID: 6425794
[TBL] [Abstract][Full Text] [Related]
11. Adrenergic enzymes in cultured mouse neuroblastoma: absence of detectable aromatic-L-amino-acid decarboxylase.
Waymire JC; Gilmer-Waymire K
J Neurochem; 1978 Sep; 31(3):693-8. PubMed ID: 28384
[No Abstract] [Full Text] [Related]
12. Effects of handling or immobilization on plasma levels of 3,4-dihydroxyphenylalanine, catecholamines, and metabolites in rats.
Kvetnanský R; Goldstein DS; Weise VK; Holmes C; Szemeredi K; Bagdy G; Kopin IJ
J Neurochem; 1992 Jun; 58(6):2296-302. PubMed ID: 1573408
[TBL] [Abstract][Full Text] [Related]
13. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.
Bozzi F; Luksch R; Collini P; Gambirasio F; Barzanò E; Polastri D; Podda M; Brando B; Fossati-Bellani F
Diagn Mol Pathol; 2004 Sep; 13(3):135-43. PubMed ID: 15322424
[TBL] [Abstract][Full Text] [Related]
14. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
15. Increase in plasma 3,4-dihydroxyphenylalanine (DOPA) appearance rate after inhibition of DOPA decarboxylase in humans.
Eldrup E; Hetland ML; Christensen NJ
Eur J Clin Invest; 1994 Mar; 24(3):205-11. PubMed ID: 8033956
[TBL] [Abstract][Full Text] [Related]
16. Alternative catecholamine pathways after tyrosine hydroxylase inhibition in malignant pheochromocytoma.
Kuchel O; Buu NT; Edwards DJ
J Lab Clin Med; 1990 Apr; 115(4):449-53. PubMed ID: 1969915
[TBL] [Abstract][Full Text] [Related]
17. Radioenzymatic assay of DOPA (3,4-dihydroxyphenylalanine).
Johnson GA; Gren JM; Kupiecki R
Clin Chem; 1978 Nov; 24(11):1927-30. PubMed ID: 709823
[TBL] [Abstract][Full Text] [Related]
18. Catecholamine metabolism in neuroblastoma.
LaBrosse EH; Comoy E; Bohuon C; Zucker JM; Schweisguth O
J Natl Cancer Inst; 1976 Sep; 57(3):633-8. PubMed ID: 10450
[TBL] [Abstract][Full Text] [Related]
19. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
20. Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion.
de Lonlay P; Simon-Carre A; Ribeiro MJ; Boddaert N; Giurgea I; Laborde K; Bellanné-Chantelot C; Verkarre V; Polak M; Rahier J; Syrota A; Seidenwurm D; Nihoul-Fékété C; Robert JJ; Brunelle F; Jaubert F
J Clin Endocrinol Metab; 2006 Mar; 91(3):933-40. PubMed ID: 16403819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
